Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by wasagastaron Jul 20, 2017 3:05pm
100 Views
Post# 26492043

RE:RE:RE:RE:RE:RE:RE:RE:I posted this in Washngton Post comments section

RE:RE:RE:RE:RE:RE:RE:RE:I posted this in Washngton Post comments section
Madheights wrote: Interesting take.  But you may be correct.  Ultimately I'm hoping that however this shakes out, that no investor(s) with deep pockets would shell out cash unless they had "confidence" in what they are investing.  Common sense.  Therefore, with that "confidence", the deal may not be as discounted as we pessimistically might think.

Although not in the past of management style or what have you, I'd like to hear an announcement that all shareholders of a certain date of record will be granted the ability to buy additional shares at such and such price with perhaps warrants, options, etc sweetening the deal.

This, I think, is a win-win.  I think the current market apprehension is all about existing shareholders feeling like they are somewhat hostage to a situation beyond their control.  So why not give an element of control?

What so you think?


Including the retail investor is great but we've had all the opportunity in the world to buy these discounted shares already.  I'd prefer they release a great series of NR's with preclinical data on brain cancer, reporting on first three with cystoscopy and the beginning of the next 6 patients at a higher dose. Let's see that - if they have it.  Then existing warrants will be purchased and the price of financing could be much much higher with 1/2 warrants that are double the price of PP share.  That's what I want to see. 
Bullboard Posts